SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported): May 19,
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
||(IRS Employer |
||Identification No.) |
|35 Wilbur Street
|(Address of principal executive offices)
||(Zip Code) |
Registrants telephone number, including area code:
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Throughout this Current Report on Form 8-K, the terms we,
us, our and Company refer to BioSpecifics Technologies Corp.
On May 19, 2014, the Company announced that new analyses of
data evaluating the use of XIAFLEX in adult men with Peyronies disease were
presented by the Companys partner, Auxilium Pharmaceuticals, Inc., at the 2014
Annual Meeting of the American Urological Association being held in Orlando,
Florida on May 16-21, 2014.
A press release regarding the announcement is attached hereto
as Exhibit 99.1.
||Financial Statements and Exhibits
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: May 19, 2014
||Biospecifics Technologies Corp.
Thomas L. Wegman |
||Name: Thomas L. Wegman |
||Title: President |